Parkinson’s patients ‘owed’ more research into using cancer drug as treatment

News

Author: AdminPublished: 2 November 2015

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

A small clinical trial showed that cancer drug Nilotinib may reverse late-stage Parkinson’s disease, potentially enabling participants to speak and walk again for the first time in years.

President and co-founder of The Cure Parkinson’s Trust, Tom Isaacs, has called for a close follow up of this small study to ensure that any opportunity for a breakthrough in the treatment of Parkinson’s is not missed.

Isaacs said: ‘Nilotinib is a case in point. When people with Parkinson’s volunteer for clinical trials and feel the type of marked improvements to their symptoms and wellbeing as those reported in this study, we owe it to them, and indeed everyone, to follow the results up as quickly and as rigorously as possible.”

Go Back

Share this story

Comments


Related articles


Finland Unity Walk

Europe

Every step counts: 2,000 people to take part in Unity Walk across Finland

Finnish Parkinson Association has organised a national Unity Walk

READ MORE

Global update

John McEnroe: “I know we’ll reach a future without Parkinson’s”

Tennis legend John McEnroe shows support for Parkinson’s patients

READ MORE
PD Warrior Insight Summit lead

Resources & Tools

PD Warrior INSIGHT Summit Into Parkinson’s 2018: virtual conference

Raising funds for the Shake It Up Foundation who strive for a cure

READ MORE